معرفی
Professor Mart Saarma is a leading figure in molecular neuroscience and biotechnology, primarily affiliated with the University of Helsinki, where he serves as Research Director at the Institute of Biotechnology. He also holds a part-time professorship at the University of Tartu, reflecting his long-standing collaboration with Estonian science. His research focuses on neurotrophic factors, particularly GDNF, CDNF, and MANF, and their therapeutic applications in neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
His research interests span Molecular Neuroscience, Neurotrophic Factors, Drug Development, Translational Medicine, and Structural Biology. He has pioneered discoveries including the identification of GDNF receptors, solving the crystal structure of the GDNF-GFRα1 complex, and co-discovering CDNF and MANF—proteins that constitute a new evolutionarily conserved family of neuroprotective agents. His work has led to the development of small-molecule GDNF mimetics with potential for oral delivery in neurodegenerative therapy.
The analysis of his recent publications reveals a consistent focus on neuroprotection, ER stress modulation, and the therapeutic translation of neurotrophic factors. His work bridges basic science and clinical application, with strong emphasis on structural insights, drug design, and preclinical validation in models of Parkinson’s, retinal degeneration, and other CNS disorders.
- Honorary Doctor of Neuroscience, University of Tartu (2022)
- Order of the White Star of Estonia, 2nd Class
- Order of the White Rose of Finland, 1st Class
- Commander's Cross of the Order of the Lion of Finland
- Member, Estonian Academy of Sciences
- Foreign Member, Royal Swedish Academy of Sciences
- Member, Academia Europaea
Mart Saarma has been a key advisor and collaborator with the University of Tartu, notably as chairman of the international scientific advisory board of the Center of Excellence in Genomics and Translational Medicine. His work involves extensive collaboration with pharmaceutical and biotech industries, including multiple patents and licensing agreements. He has also held leadership roles in major scientific initiatives, including Vice-President of the European Research Council and member of the EU Human Brain Project. His research group continues to explore novel neuroprotective strategies and drug candidates.
He is actively involved in international research networks and leads a dynamic research team focused on neurotrophic biology and therapeutic innovation. His laboratory maintains strong ties with the Institute of Chemistry at the University of Tartu, particularly in the development of GDNF mimetics.
